Presentation is loading. Please wait.

Presentation is loading. Please wait.

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma  Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Published byBenny Muljana Modified over 4 years ago

Similar presentations

Presentation on theme: "Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma  Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,"— Presentation transcript:

1 Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma  Po-Kuei Hsu, MD, Chien-Sheng Huang, MD, Bing-Yen Wang, MD, Yu-Chung Wu, MD, Wen-Hu Hsu, MD  The Annals of Thoracic Surgery  Volume 97, Issue 5, Pages (May 2014) DOI: /j.athoracsur Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Overall survival. (A) All patients. (B) N+ patients. (C) All propensity-matched patients. (D) Propensity-matched N+ patients. Red lines indicate postoperative chemoradiation group; black lines indicate surgery alone group. (CRT = chemoradiation therapy.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Disease-free survival. (A) All patients. (B) N+ patients. (C) All propensity-matched patients. (D) Propensity-matched N+ patients. Red lines indicate postoperative chemoradiation group; black lines indicate surgery alone group. (CRT = chemoradiation therapy.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma  Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,"

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Benny Weksler, MD, Jennifer L. Sullivan, MD 

Benny Weksler, MD, Jennifer L. Sullivan, MD 
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Collision Tumor of Esophagus: Report of Three Cases

Collision Tumor of Esophagus: Report of Three Cases
Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.
Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.
Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T
Prognostic Value of Different Lymph Node Staging Methods in Esophageal Squamous Cell Carcinoma After Esophagectomy  San-Gang Wu, MD, Feng-Yan Li, MD,

Prognostic Value of Different Lymph Node Staging Methods in Esophageal Squamous Cell Carcinoma After Esophagectomy  San-Gang Wu, MD, Feng-Yan Li, MD,
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases
High Expression of Zinc-Binding Protein-89 Predicts Decreased Survival in Esophageal Squamous Cell Cancer  Shu-Mei Yan, MD, Hui-Ni Wu, MB, Fan He, MD,

High Expression of Zinc-Binding Protein-89 Predicts Decreased Survival in Esophageal Squamous Cell Cancer  Shu-Mei Yan, MD, Hui-Ni Wu, MB, Fan He, MD,
Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma
Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease  Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease  Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,
Factors Predicting Recurrence and Postrecurrence Survival in Completely Resected Thymic Carcinoma  Yi-Ting Yen, MD, Wu-Wei Lai, MD, Kai-Wei Chang, MD,

Factors Predicting Recurrence and Postrecurrence Survival in Completely Resected Thymic Carcinoma  Yi-Ting Yen, MD, Wu-Wei Lai, MD, Kai-Wei Chang, MD,
Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,
Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival  Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival  Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,
Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C
Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer  Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer  Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Similar presentations

Ads by Google